Britain and America have hammered out a landmark bilateral deal that will maintain no duties on UK medicine shipments being sold in the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to boost spending on medicines through the National Health Service (NHS). This commitment ensures that duties on these vital exports will remain at zero for a duration of the next three years.
This agreement follows recent threats to dramatically increase import taxes on patented drug products, with figures mentioned up to double the cost.
"This arrangement between the Britain strengthens the global environment for innovative medicines and introduces much-needed equity to American-British pharmaceutical trade," a release noted.
Economic Importance
Pharmaceuticals constitute one of the the United Kingdom's most significant exports to the America, which is easily the biggest market for large British pharmaceutical firms.
Export figures show that in the 12 months leading up to last September, the UK exported medicines totaling billions to the US. This figure made up nearly one-fifth of British export trade in that timeframe.
"This guarantee protects employment, increases investment and paves the way for the UK to emerge as a international leader for medical research," a minister commented.
Specific UK Commitments
The agreement involves several key changes from the UK:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must return to the NHS to control costs will be restricted at fifteen percent. Previously, refunds topped 20%.
Industry Background
The pact comes amid a ongoing row between the pharmaceutical industry and the ministers over spending levels and regulatory access.
This friction were intensified by assertions that American patients were charged several times more for the identical medicines than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward American operations.
A senior figure publicly accepted that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its resources over the previous ten-year period.
